Anacor Pharmaceutical

Anacor Pharmaceuticals is a biopharmaceutical company that engages in developing small-molecule therapeutics from its boron chemistry platform. It focuses on developing topical applications of its compounds to treat fungal, bacterial, and inflammatory diseases.

The company’s primary product candidate, AN2690, is a novel topical antifungal for the treatment of toenail onychomycosis, a fungal infection of the nail and nail bed. It is also developing AN2728, an anti-inflammatory product candidate for the treatment of psoriasis; AN0128, a product candidate that has antibiotic and anti-inflammatory properties; and AN2718, which is in preclinical development for the topical treatment of vaginal candidiasis and tineapedis.

Anacor Pharmaceutical headquartered in United States, North America, operates in the Biotechnology, Health Care, Pharmaceutical sector. The company focuses on Biotechnology and has secured $53.8B in funding across 120 round(s). With a team of 51-100 employees, Anacor Pharmaceutical is actively contributing to advancements in Biotechnology. Their latest funding round, Series E - Anacor Pharmaceutical, raised $50.0M. Discover more about their projects, partnerships, and impact on our platform.